Humoral Rejection after Pediatric Heart Transplantation: A Case Report

Abstract

Humoral rejection was observed 2 years after heart transplantation in a 10-year-old African American girl with sickle cell disease. Hemodynamic compromise developed, and the patient started treatment with extracorporeal membrane oxygenation within 24 hours of admission. With cellular rejection initially believed to be the cause, administration of thymoglobulin and high-dose steroids was initiated. Human leukocyte antigen antibody analysis revealed high titers of donor-specific class I and II antibodies. Aggressive treatment for antibody-mediated rejection was started with plasmapheresis and administration of intravenous immune globulin and ritux-imab. The patient displayed clinical signs of infection and was treated with antimicrobial, antiviral, and antifungal agents. Computed tomography of the chest suggested asperigillous infection. The patient underwent a left upper lobectomy. The patient recovered and has done well, now 4 years after having received the heart transplant. Antibody-mediated rejection should be considered early in heart transplant patients presenting with hemodynamic compromise and may respond to aggressive antibody and B cell–directed therapy. Vigilance for secondary infections, especially during treatment for rejection, is crucial.

Get full access to this article

View all access options for this article.

References

Webber

. The current state of, and future prospects for, cardiac transplantation in children. Cardiol Young. 2003;13(1): 64–83.

Casarez

Perens

Williams

. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant. 2007;26(2):114–119.

Webber

Naftel

Parker

. Late rejection episodes more than 1 year after pediatric heart transplantation: Risk factors and outcomes. J Heart Lung Transplant. 2003;22(8):869–875.

Zangwill

Ellis

Zlotocha

. The virtual cross-match—a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant. 2006;10(1):38–41.

Shaddy

Fuller

. The sensitized pediatric heart transplant candidate: Causes, consequences, and treatment options. Pediatr Transplant. 2005;9(2):208–214.

Stewart

Winters

Fishbein

. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–1720.

Geiger

Harake

Halnon

Alejos

Levi

. Screening for rejection in symptomatic pediatric heart transplant recipients: The sensitivity of BNP. Pediatr Transplant. 2008;12(5): 563–569.

Berg

. Pediatric heart transplantation: A clinical overview. Crit Care Nurs Q. 2002;25(3):79–87.

Reed

Demetris

Hammond

. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153–159.

10.

Aranda

Scornik

Normann

. Anti-CD20 monoclonal antibody (Rituximab) therapy for acute cardiac humoral rejection: A case report. Transplantation. 2002;73(6): 907–910.

11.

Zangwill

Ellis

Stendahl

. Practical application of the virtual crossmatch. Pediatr Transplant. 2007;11(6):650–654.

12.

Takemoto

Zeevi

Feng

. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033–1041.

13.

Wieland

Liebold

Jiagiello

Retzl

Birnbaum

. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant. 2005;24(1):102–104.

14.

Papanicolaou

White

. Invasive pulmonary aspergillosis, part 2: Treatment. J Respir Dis. 2008;29(11):429–434.

15.

Singh

Husain

. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant. 2009;9(suppl 4): S180–S191.

16.

Saad

DePestel

Carver

. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12):1730–1744.